CHICAGO — The cancer drug Trodelvy reduced the risk of tumors progressing by 34% compared to chemotherapy in patients with the most common form of metastatic breast cancer — an outcome reported Saturday that met the goals of a large clinical trial conducted by its maker, Gilead Sciences.
Despite the positive results, the future of Trodelvy as a new treatment for women with HR-positive, HER2-negative breast cancer remains unclear. Patients in the trial had advanced disease, but the drug only provided a relatively small benefit. And there’s no definitive evidence yet that Trodelvy will help this group of breast cancer patients live longer.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
